Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ACCS for Gingivitis
NCT02071199Phase 1Completed
- Sponsor
- Noveome Biotherapeutics
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ST266 in gingivitis (3 arms), sponsored by Noveome Biotherapeutics. Primary endpoint: Incidence of adverse/serious adverse events at 4 weeks. Started Mar 2014; status: completed.
02
Drugs
ST266
03
Conditions
gingivitis
Beyond the preview
Go deeper on NCT02071199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071199.